CodeMap® Compliance Briefing: 10/31/2018
Editor's Correction: Our 10/4/2018 Compliance Briefing described significant changes to the codes and payment amounts for BRCA1 and BRCA2 gene tests for hereditary breast and ovarian cancer. The final analysis of Medicare payment for full BRCA1/BRCA2 sequence and deletion/duplication testing assumed that existing CPT® code 81162 would be deleted from the 2019 CPT. This was incorrect.
The 2019 CPT still includes 81162 with only a minor revision to the description and instructs that it is to be used to report full BRCA1/BRCA2 sequence and deletion/duplication testing when performed on the same date of service.
Sorry, access to this content requires a current subscription.
Click here for publications catalog.
CPT copyright 2017 American Medical Association. All rights reserved.
* The responsibility for the content of any "National Correct Coding Policy" included in this product is with the Centers for Medicare and Medicaid
Services and no endorsement by the AMA is intended or should be implied. The AMA disclaims responsibility for any consequences or liability attributable to or related
to any use, nonuse, or interpretation of information contained in this product.